Orgenesis Announces Results From A Real-World Study Of ORG-101 CAR-T Therapy In Patients With CD19+ Acute Lymphoblastic Leukemia; Top-Line Efficacy And Safety Data From The Study Had A Complete Response Of 82% In Adult Patients And 93% In Pediatric Patients

Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patients and 6% in pediatric patients in a real-world study

Data indicate a potentially favorable safety profile with a lower incidence of Cytokine Release Syndrome

Encouraged by the positive data, Harley Street Healthcare Group along with its partners intends to commit resources to set up a Global Cancer Initiative with a focus to democratize Advanced Therapies and support further clinical development sharing the risks and rewards

GERMANTOWN, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced positive clinical trial results for a real-world study of CD19 CAR-T therapy, ORG-101, in patients with CD19+ Acute Lymphoblastic Leukemia (B-cell ALL). Harley Street Healthcare Group intends to set up a Global Cancer Initiative through its joint venture with Orgenesis, with a focus to democratize Advance Therapies and support further clinical development.